COVID-19 pandemic and deficiencies of research facility is based on atomic testing limit and reagents, numerous analytic test makers have created and started offering fast and simple gadgets to encourage testing outside of lab settings. These testing units depend either on recognition of proteins from the COVID-19 infection in respiratory examples (for example sputum, throat swab) or recognition, in blood or serum, of human antibodies created because of contamination.
Nucleic acid-based tests are sensitive in early identification of disease, and have been widely used during the COVID-19 pandemic. These tests ordinarily depend on a decades-old system called reverse transcription polymerase chain reaction, or RT-PCR.
The COVID-19 test kits are very important and demanding product in the present days, due to growth of COVID-19 pandemic. This kit is available mainly in two types: tests that identify proteins related with the infection, known as immunoassays, and tests that detect the virus’s hereditary code, known as nucleic corrosive or atomic tests. Due to shortage of laboratory-based molecular testing and reagents, the manufacturers of diagnostic test have been selling devices to encourage testing outside of research facility settings.
Equipment and Extraction Kits, rRT-PCR Test Kits, Reagents9
Nasopharyngeal swab, Oropharyngeal swab, Nasal swab, Others
Pathology Centre, Pharmacy Store, Clinics, Hospitals, Others
However, before the recommendation of tests, they should be approved in the fitting populations and settings. Deficient tests may miss patients with dynamic contamination and classify the patients as having the sickness which doesn’t exist, further hampering ailment control efforts. At present, based on the information, WHO prescribes the utilization of new point- of-care immunodiagnostic tests only in research settings. They should not be used in clinical decision making and other settings, until required information is available for specific indications.
Speedy occurrence of highly infectious disease COVID-19 at global level and constant growth in number of population infected from Corona virus boost the Demand of COVID-19 kit globally. According to World Health Organization (WHO), as of 13th April 2020, 7,47,546 confirmed corona virus cases were recorded globally. Global Healthcare Industry is witnessing the shortage of testing kits to test COVID-19 in the difficult time of rapid growth in infection worldwide. Rapid collection and testing of individual meeting the suspect case for COVID-19 is a priority and essential to control outbreak of COVID-19 which boosts the market growth.
QIAGEN serves more than 500,000 customers around the globe, all seeking insights from the building blocks of life – DNA, RNA and proteins. We deliver Sample to Insight solutions for molecular testing, propelling QIAGEN customers from start to finish to unlock new insights. This is how we make improvements in life possible.
Our product portfolio spans the full range of molecular testing applications. We lead the world in products to extract, purify and stabilize DNA, RNA and protein from biological samples, even the most difficult, a critical first step in each customer’s quest to generate new insights. Our novel testing technologies can target single molecular variants – or hundreds. QIAGEN software analyzes and interprets vast amounts of data to deliver valuable insights. Our automation systems bring together all of these steps in seamless end-to-end workflows.
QIAGEN has received emergency use authorization from the U.S. Food and Drug Administration (FDA) for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test for use in diagnosing patients infected with the novel COVID-19 coronavirus.
We achieve this by bringing The Science of Sure® to life. The Science of Sure reflects who we are as a leading innovator in women’s health, helping healthcare professionals around the world diagnose and treat their patients with precision, certainty and confidence.
With groundbreaking technology at the core, our innovations are designed to achieve exceptional clinical results, making it possible to detect, diagnose and treat illnesses and other health conditions earlier and more effectively.
By providing early and accurate results, our goal is to minimize doubt and maximize the confidence our customers and their patients have in their decisions and diagnoses. Because when their health is in question, nothing is more important than being sure.
Hologic’s Molecular Test for the Novel Coronavirus, SARS-CoV-2, Receives FDA Emergency Use Authorization
We understand that the first step to living your best life is good health. Everything we make is designed to help you do just that. That’s our commitment to building life-changing technologies that keep your heart healthy, nourish your body at every stage of life, help you feel and move better, and bring you information, medicines and breakthroughs to manage your health.
From removing the regular pain of fingersticks as people manage their diabetes to connecting patients to doctors with real-time information monitoring their hearts, from easing chronic pain and movement disorders to testing half the world’s blood donations to ensure a healthy supply, our purpose is to make the world a better place by bringing life-changing health technologies to the people who need them. That’s our commitment to helping you live your best life.
Abbott has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes.
Thermo Fisher Scientific is the world leader in serving science and with that position comes a great sense of responsibility to the global community. We realize we have the ability to make a significant positive impact on society in many different ways. The products and services we provide to our customers help them tackle some of the world’s greatest challenges. We also contribute by operating responsibly and by giving back to the communities in which we live and work.
Thermo Fisher and Ford Partner to Scale Production of Collection Kits for COVID-19 Tests
Over a decade ago, Cepheid set the standard for innovation in automated molecular diagnostics — and we’ve never looked back. Today, even with the largest installed base of any molecular platform, Cepheid is constantly innovating and evolving its capabilities. The GeneXpert® System has been heralded as game-changing by healthcare leaders across the globe — enabling institutions of any size, from small medical clinics to high-volume reference laboratories and hospitals, to access the speed and accuracy of molecular diagnostics. Cepheid’s growing Xpert® test menu spans multiple clinical applications including healthcare-associated infections, sexual health, critical infectious disease, virology, and oncology.
Cartridges can be used to detect COVID-19 in approximately 45 minutes in Cepheid’s more than 23,000 automated GeneXpert® Systems worldwide